- Home
- LXRX vs CMPS Comparison
LXRX vs CMPS Comparison
Compare LXRX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CMPS
- Stock Information
- Founded
- LXRX 1995
- CMPS 2020
- Country
- LXRX United States
- CMPS United Kingdom
- Employees
- LXRX N/A
- CMPS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- CMPS Health Care
- Exchange
- LXRX Nasdaq
- CMPS Nasdaq
- Market Cap
- LXRX 428.8M
- CMPS 487.4M
- IPO Year
- LXRX 2000
- CMPS 2020
- Fundamental
- Price
- LXRX $1.52
- CMPS $6.34
- Analyst Decision
- LXRX Buy
- CMPS Strong Buy
- Analyst Count
- LXRX 5
- CMPS 7
- Target Price
- LXRX $3.23
- CMPS $17.00
- AVG Volume (30 Days)
- LXRX 2.6M
- CMPS 1.5M
- Earning Date
- LXRX 11-11-2025
- CMPS 10-30-2025
- Dividend Yield
- LXRX N/A
- CMPS N/A
- EPS Growth
- LXRX N/A
- CMPS N/A
- EPS
- LXRX N/A
- CMPS N/A
- Revenue
- LXRX $58,432,000.00
- CMPS N/A
- Revenue This Year
- LXRX $67.21
- CMPS N/A
- Revenue Next Year
- LXRX N/A
- CMPS N/A
- P/E Ratio
- LXRX N/A
- CMPS N/A
- Revenue Growth
- LXRX 1504.83
- CMPS N/A
- 52 Week Low
- LXRX $0.28
- CMPS $2.25
- 52 Week High
- LXRX $2.18
- CMPS $6.63
- Technical
- Relative Strength Index (RSI)
- LXRX 70.28
- CMPS 73.27
- Support Level
- LXRX $1.28
- CMPS $5.54
- Resistance Level
- LXRX $1.42
- CMPS $6.62
- Average True Range (ATR)
- LXRX 0.10
- CMPS 0.33
- MACD
- LXRX 0.02
- CMPS 0.08
- Stochastic Oscillator
- LXRX 81.00
- CMPS 86.39
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.